Clients are, by necessity, concerned about their financial health when they start discussing ART.  As you know, there are only about 13 American States and fewer other Countries that offer insurance coverage for infertility.  So, for better or for worse, treatment options are driven by the thickness of the wallet.

Those who have kept up, know that PGS or preimplantation genetic screening is offered to older patient having a history of miscarriage.   A new study will be published in the June issue of Human Fertility which will effectively remove PGS as a testing option.  The British Fertility Society will suggest that PGS only be offered to patients who are participating in randomized clinical trials.

Why the change?  It seems, so say the authors of the publication, that there is no difference in live birth rates for those that use PGS and those that do not.  If there is no difference, why not save money and direct it toward a treatment modality which is more likely to help increase your odds of having a child. 

As the saying goes, the jury is still out on this issue.  You will never know if PGS will help or not until you ask your Reproductive Endocrinologist to explain why your situation is different than those persons who were included in the "Human Fertility" study.  At the very least, you owe it to yourself and your future child the respect of being a good patient and an educated consumer.